Insider's View of the Current Issues Affecting Pharma Companies
Arguably no health care sector is currently experiencing more disruption than the pharmaceutical industry. Current efforts by public payers to change the payment model for prescription drugs and minimize – or at least modify – the role of PBMs could not only have significant impact within Medicare and Medicaid but also create ripple effects into the commercial market.
Leavitt Partners has experts with deep pharmaceutical experience who can give audiences an insider’s view of the current issues affecting pharma companies, including the political and regulatory environment, value-based payment arrangements, the trend toward cost effectiveness assessments, and drug pricing and transparency requirements.
LEAVITT PARTNERS TOPIC EXPERT SPEAKERS:
Former President and CEO of the Food and Drug Law Institute; Former Chief of Staff for the FDA; Georgetown University Law Center, JD (View Bio)
Ralph previously served as counsel at Faegre Baker Daniels where he provided legal services, including FDA-related matters, corporate compliance, the design and implementation of multiple cross-disciplinary, corporate legal strategies, corporate law department organization and management, and general corporate counseling. Ralph has also served as General Counsel for Guidant CRM and Chief Compliance Officer for Guidant. (View Bio)